A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.